HMHugo Marques

Hugo Marques

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hugo Marques has a total of 153 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Association of Low-Attenuation Noncalcified Plaque Shape and Degree of Intraplaque Embeddedness Using Atherosclerotic Imaging–enabled Quantitative CT with Acute Coronary Syndrome

    by Shant Malkasian, Nick S. Nurmohamed, Hyuk-Jae Chang, Andrew D. Choi, Hugo Marques, Sabee Molloi, Alexander van Rosendael, Benjamin J.W. Chow, Daniele Andreini, Edoardo Conte, et al.

    Adverse low-attenuation noncalcified plaque morphology using atherosclerotic imaging-enabled quantitative CT (ie, lobular, bean, or spherical low-attenuation noncalcified plaque shape or low-attenuation noncalcified plaque with ≥ 180° of embeddedness) was independently associated with acute coronary syndrome.


  • Open Access

    Deep-learning denoising for ultrahigh-resolution photon-counting detector CT: phantom and in vivo evaluation of non-calcified coronary plaques

    by Sardi Hyska, Muhammad Taha Hagar, José Osoria-Velasquez, Nicola Fink, Jens Ricke, Moritz C. Halfmann, Hugo Marques, Elliot McVeigh, George Wesbey, Pál Maurovich-Horvat, et al.

    To assess the value of convolutional neural network (CNN)-based denoising for the evaluation of non-calcified coronary plaques on ultrahigh-resolution (UHR) photon-counting detector (PCD) coronary CT angiography (CCTA). A dynamic phantom containing lipid-rich and fibrotic plaques with 50%-diameter stenosis (PDS) was scanned on PCD-CT under varying conditions. For in-vivo imaging, consecutive patients with non-calcified coronary plaques (NCPs) who underwent CCTA with PCD-CT were included. Image series were reconstructed using a sharp vascular kernel (Bv64) with slice thicknesses of 0.2 mm/0.4 mm, quantum iterative reconstruction (QIR) levels 3/4, and with/without CNN denoising. Phantom-based line-profile analysis yielded edge-width at half maximum (EWHM) and 10–90% rise distance as sharpness metrics. Plaque contrast-to-noise ratio (CNR) and PDS were assessed in the phantom and in patients. Two readers evaluated subjective image quality (noise, diagnostic confidence) using a four-point Likert scale. Pairwise comparisons were performed using a Bonferroni-corrected p < 0.002 for significance. Fifty-five patients (median age 74 [66.5–78] years; 19 women) with 97 NCPs were included. Phantom-based sharpness metrics remained unchanged after denoising (all pairwise p > 0.051). CNN denoising increased plaque CNR consistently in the phantom (fibrotic: 0.80–1.64 to 0.92–2.06; lipid-rich: 0.21–0.34 to 0.35–0.46) and in vivo (0.99–2.07 to 1.37–2.92, all pairwise p < 0.001). Denoising did not alter PDS values in phantom or in vivo plaques (all pairwise p > 0.006). Subjective image noise and diagnostic confidence improved across all reconstructions (all pairwise p < 0.001). CNN-based denoising of UHR PCD-CT improves image quality of non-calcified coronary plaques, while preserving sharpness and quantitative stenosis metrics.

  • Pericoronary Adipose Tissue Attenuation in Patients with Future Acute Coronary Syndromes: The ICONIC Study

    by Alan C. Kwan, Evangelos Tzolos, Eyal Klein, Donghee Han, Andrew Lin, Keiichiro Kuronuma, Billy Chen, Guadalupe Flores Tomasino, Heidi Gransar, Piotr J. Slomka, et al.

    Pericoronary adipose tissue attenuation, a marker of coronary inflammation, shows minimal quantitative differences between patients with and without future incident acute coronary syndromes in a matched case-control multicenter cohort of patients who underwent coronary CT angiography but is independently associated with future incident acute coronary syndromes in adjusted survival analyses.


  • Rapid Plaque Progression Is Independently Associated With Hyperglycemia and Low HDL Cholesterol in Patients With Stable Coronary Artery Disease: A PARADIGM Study

    by Danilo Neglia, Chiara Caselli, Erica Maffei, Filippo Cademartiri, Antonella Meloni, Eduardo Bossone, Luca Saba, Sang-Eun Lee, Ji Min Sung, Daniele Andreini, et al.

    BACKGROUND: We assessed whether combinations of cardiometabolic risk factors independently predict coronary plaque progression (PP) and major adverse cardiovascular events in patients with stable coronary artery disease. METHODS: Patients with known or suspected stable coronary artery disease (60.9±9.3 years, 55.4% male) undergoing serial coronary computed tomography angiographies (≥2 years apart), with clinical characterization and follow-up (N=1200), were analyzed from the PARADIGM study (Progression of Atherosclerotic Plaque Determined by Computed Tomographic Angiography Imaging). Plaque volumes measured in coronary segments (≥2 mm in diameter) were summed to provide whole heart plaque volume (mm 3 ) and percent atheroma volume (plaque volume/vessel volume×100; %) per patient at baseline and follow-up. Rapid PP was defined as a percent atheroma volume increase of ≥1.0%/y. Major adverse cardiovascular events included nonfatal myocardial infarction, death, and unplanned coronary revascularization. RESULTS: In an interscan period of 3.2 years (interquartile range, 1.9), rapid PP occurred in 341 patients (28%). At multivariable analysis, the combination of cardiometabolic risk factors defined as metabolic syndrome predicted rapid PP (odds ratio, 1.51 [95% CI, 1.12–2.03]; P =0.007) together with older age, smoking habits, and baseline percent atheroma volume. Among single cardiometabolic variables, high fasting plasma glucose (diabetes or fasting plasma glucose >100 mg/dL) and low HDL-C (high-density lipoprotein cholesterol; P 130/85 mm Hg) was an independent predictor of events (hazard ratio, 1.79 [95% CI, 1.10–2.90]; P =0.018) together with family history, baseline percent atheroma volume, and rapid PP. CONCLUSIONS: In patients with stable coronary artery disease, the combination of hyperglycemia with low HDL-C is associated with rapid PP independently of other risk factors, baseline plaque burden, and treatment. The combination of hyperglycemia with high systemic blood pressure independently predicts the worse outcome beyond PP. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02803411.


  • Implications of three different testing strategies in the diagnostic approach to patients with stable chest pain and low pretest probability of obstructive coronary artery disease

    by Pedro M. Lopes, António M. Ferreira, Francisco Albuquerque, Pedro Freitas, Pedro de Araújo Gonçalves, João Presume, João Abecasis, Sara Guerreiro, Ana Coutinho Santos, Carla Saraiva, et al.


  • Prognostic Significance of Nonobstructive Left Main Coronary Artery Disease in Patients With and Without Diabetes: Long-Term Outcomes From the CONFIRM Registry

    by Juhwan Lee, Kashif Shaikh, Rine Nakanishi, Heidi Gransar, Stephan Achenbach, Mouaz H. Al-Mallah, Daniele Andreini, Jeroen J. Bax, Daniel S. Berman, Filippo Cademartiri, et al.

  • Open Access

    Influence of age on the diagnostic value of coronary artery calcium score for ruling out coronary stenosis in symptomatic patients

    by P Lopes, F Albuquerque, P Freitas, P A Goncalves, J Presume, S Guerreiro, J Abecasis, A C Santos, C Saraiva, M Mendes, et al.

    Background: The 2021 Guideline for the Evaluation of Chest Pain supports the use of coronary artery calcium (CAC) score as a reasonable first-line test to identify patients with a low likelihood of obstructive coronary artery disease (CAD) who may not require additional testing (class IIa, LOE B). However, a recent study from a large cohort of Northern European patients raised concerns about the added diagnostic value of CAC=0 in younger patients. The aim of this study was to assess the influence of age on the value of CAC=0 in symptomatic patients undergoing coronary computed tomography angiography (CCTA). Methods: We conducted a two-center cross-sectional study assessing symptomatic patients with suspected CAD who underwent CAC score and CCTA. Key exclusion criteria were age <30 years, known CAD, suspected acute coronary syndrome, or symptoms other than chest pain or dyspnea. Pretest probability of obstructive CAD was calculated based on age, sex and symptom typicality, according to the guideline-recommended method. Obstructive CAD was defined as any luminal stenosis ≥50% on CCTA. The diagnostic likelihood ratios and negative predictive values (NPV) were used to assess the diagnostic value of a CAC score of 0 to rule out obstructive CAD. Results: A total of 2043 patients (mean age 60±11 years, 60% women) of whom 990 (48.5%) had a CAC score of 0 were included in the analysis. Symptom characteristics were: 38% non-anginal chest pain, 30% atypical angina, 19% dyspnea, and 13% typical chest pain. Overall, the prevalence of obstructive CAD was 12.8% (n=262). Pretest probability of obstructive CAD increased progressively with age, from 6.0% in patients young than 50 years to 20.7% in those 70 years or older. Contrariwise, the prevalence of patients with a CAC score = 0 decreased from 77% in patients younger than 50 years, to 26% in those who where 70 years or older. The added diagnostic value of a CAC score = 0 was lower in younger patients, with negative likelihood ratios ranging from 0.36 (64% decrease in the likelihood of CAD) in patients younger than 50 years, to 0.09 and 0.10 (∼90% decrease in the likelihood of CAD) in those aged 60–69 years and 70 years or older, respectively – Figure 1. Despite this, the prevalence of obstructive CAD among patients with a CAC score = 0 was low across all age groups: 2.4% (i.e., NPV = 97.6%) in those younger than 50 years, 3.0% (NPV = 97.0%) among those aged 50–59 years, 1.5% (NPV = 98.5%) in patients between 60 and 69 years, and 2.0% (NPV = 98.0%) among those 70 years or older. Conclusions: In a cohort of symptomatic patients undergoing CCTA for suspected CAD, the added diagnostic value of a CAC score of zero decreases significantly at younger ages. However, this “diminishing return” of CAC in younger patients if offset by their lower pretest probabilities, yielding high negative predictive values independently of age. Funding Acknowledgement: Type of funding sources: None.

  • Aspirin and Statin Therapy for Nonobstructive Coronary Artery Disease: Five-year Outcomes from the CONFIRM Registry

    by Praveen Indraratna, Christopher Naoum, Sagit Ben Zekry, Heidi Gransar, Philipp Blanke, Stephanie Sellers, Stephan Achenbach, Mouaz H. Al-Mallah, Daniele Andreini, Daniel S. Berman, et al.

    In participants with nonobstructive coronary artery disease at coronary CT angiography, baseline statin use was associated with fewer major adverse cardiovascular events over a mean follow-up of 5.... Purpose In this cohort study, 5-year data from the Coronary CT Angiography Evaluation for Clinical Outcomes: An International Multicenter Registry (ie, CONFIRM) were examined to identify associatio...


  • Top Cited Papers
    Open Access

    CT ​Evaluation ​by ​Artificial ​Intelligence ​for ​Atherosclerosis, Stenosis and Vascular ​Morphology ​(CLARIFY): ​A ​Multi-center, international study

    by Andrew D. Choi, Hugo Marques, Vishak Kumar, William F. Griffin, Habib Rahban, Ronald P. Karlsberg, Robert K. Zeman, Richard J. Katz, James P. Earls


  • Open Access

    Modified continuity equation using left ventricular outflow tract three‐dimensional imaging for aortic valve area estimation

    by Pedro Pinto Teixeira, Ruben Ramos, Pedro Rio, Luísa Moura Branco, Guilherme Portugal, Ana Abreu, Ana Galrinho, Hugo Marques, Luísa Figueiredo, Rui Cruz Ferreira

    Purpose: Aortic valve area (AVA) is usually estimated by the continuity equation (CE) in which the left ventricular outflow tract (LVOT) area is calculated assuming a circular shape. This study aimed to compare measurements of LVOT area using standard 2D transthoracic echocardiography (2DTTE), 3D transesophageal echocardiography (3DTEE), and multidetector computed tomography (MDCT) and assess their relative impact on AVA estimated by the CE.Methods and Results: We prospectively enrolled 60 patients with severe aortic stenosis (AS) referred for transcatheter aortic valve replacement (TAVR) who systematically underwent 2DTTE, 3DTEE, and MDCT. Mean LVOT areas obtained by 2DTTE (3.28±0.66 cm2) and 3DTEE (3.95±0.90 cm2) were significantly underestimated when compared to the mean MDCT LVOT area (4.31±0.99 cm2). LVOT was rather elliptical than round, with a mean eccentricity index of 1.47 (ratio of maximum to minimum LVOT diameters) assessed by MDCT. Mean TTE AVA estimated by the CE was 0.62±0.20 cm2. Substitution of 2DTTE LVOT area by 3DTEE LVOT area in the CE resulted in AVA of 0.74±0.24 cm2, while using MDCT LVOT area held an AVA of 0.80±0.24 cm2. MDCT‐derived AVA was similar to MDCT planimetric AVA and allowed 24% of patients to be reclassified from severe to moderate AS.Conclusions: 2DTTE and 3DTEE underestimate LVOT area when compared to MDCT with significant impact on AVA estimation. Assessment through MDCT fusion AVA may be of incremental value in patients with discrepant severity criteria for AS.